Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799692 | 0.85 | CYP3A4 (0.45) | CYP3A4SMN1; SMN2TAAR1CYP2D6SLC6A2 | |
| SCHEMBL2769287 | 0.83 | FAAH (0.36) | SMN1; SMN2NPSR1ALDH1A1GAAMAPT | |
| SCHEMBL2176328 | 0.81 | CTSS (0.41) | NPSR1ALDH1A1ATMBACE1 | |
| SCHEMBL2078615 | 0.80 | CYP3A4 (0.45) | CYP3A4SMN1; SMN2TAAR1CYP2D6SLC6A2 | |
| SCHEMBL2078007 | 0.77 | PTGES (0.35) | CYP3A4BACE1 | |
| SCHEMBL15304448 | 0.74 | CYP3A4 (0.43) | CYP3A4SMN1; SMN2TAAR1CYP2D6SLC6A2 | |
| SCHEMBL2628499 | 0.74 | CYP3A4 (0.43) | CYP3A4SMN1; SMN2TAAR1CYP2D6SLC6A2 | |
| SCHEMBL4357081 | 0.74 | CYP3A4 (0.50) | CYP3A4TAAR1CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL12015403 | 0.72 | CYP3A4 (0.52) | CYP3A4SMN1; SMN2TAAR1CYP2D6SLC6A2 | |
| SCHEMBL25391472 | 0.72 | TAAR1 (0.67) | CYP3A4SMN1; SMN2TAAR1CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163909-B2 | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7951838-B2 | Substituted spirocyclic chromanamine compounds as Beta-Secretase modulators and methods of use | AMGEN INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7803809-B2 | Substituted pyrano [2,3-b] pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-09-28 | — | — | US | disclosed |
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120774-A1 | Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use | BACE1, APP, BACE2 | CYP3A4 788/4885SMN1; SMN2 1407/4885TAAR1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.